Gilead Sciences, Inc. at Wells Fargo Healthcare Conference Transcript
Awesome. Thank you very much for joining us today. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo, and I'm joined by Dr. Dietmar Berger, Gilead's Chief Medical Officer. Thank you very much, Dietmar, for joining us today for the first time.
Thanks for having me. Yeah, of course.
Awesome. So Gilead has been a regular. This is fifth year in a row at Wells Fargo Conference, first time for Dietmar. So we'll be excited to have some R&D discussion here.
Questions & Answers
So Dietmar, let's just talk a little bit about the pipeline focus right now. So it does seem like you have a mix of like obviously building on HIV where you have a leadership and then oncology, some data set coming in immunology as well. So
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
